Why it matters: The study confirms that cannabis prohibition in certain states has unintentionally led to the popularity of hemp-derived cannabinoids, specifically delta-8 THC. This highlights the demand for alternative options in states where legal cannabis is not accessible.
What they are saying: The study, published by the American Medical Association, examines trends in emerging cannabinoids like delta-8 THC, CBG, and CBN. Researchers found that past-year cannabis use was associated with the use of these emerging cannabinoids. Furthermore, residing in states with medical or recreational cannabis laws was negatively associated with delta-8 THC use.
The big picture: The market for hemp-derived cannabinoids has significantly grown since the legalization of hemp and hemp-derived products in the U.S. The popularity of delta-8 THC, a less potent but still psychoactive cannabinoid, has especially increased. The study highlights the need for industry standards to protect consumers and raises concerns about the effects of delta-8 THC on adolescents and young adults.
What to watch: The regulation of hemp-derived cannabinoids has become a pressing issue. Some states have banned or regulated intoxicating cannabinoids separately from CBD. The DEA has clarified that synthetic cannabinoids and delta-8 THC synthesized from legal CBD are considered prohibited controlled substances. The next iteration of the Farm Bill, expected in 2024, may address these issues.
My take: The study provides valuable insights into the market for hemp-derived cannabinoids and their use. It emphasizes the unintended consequences of cannabis prohibition and the need for regulation to ensure consumer safety. As the industry continues to evolve, it is crucial to monitor how policymakers address these issues and protect public health.
